Are We Approaching a Change in Paradigm in PET/CT Imaging of Solid Gastrointestinal (or Digestive) Tract Tumors With the Clinical Application of FAPI Imaging?-Reference-Cited by-同舟云学术

Are We Approaching a Change in Paradigm in PET/CT Imaging of Solid Gastrointestinal (or Digestive) Tract Tumors With the Clinical Application of FAPI Imaging?

Published:2023-02-08 Issue:4 Volume:48 Page:318-319
ISSN:1536-0229
Container-title:Clinical Nuclear Medicine
language:en
Short-container-title:Clin Nucl Med

Author:

Delgado Bolton Roberto C.¹^ORCID,Calapaquí Terán Adriana K.²^ORCID,Herrmann Ken³^ORCID,Fanti Stefano⁴^ORCID,Giammarile Francesco⁵^ORCID

Affiliation:

1. Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), Logroño, La Rioja

2. Department of Pathology, University Hospital “Marqués de Valdecilla,” Santander, Spain

3. Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)–University Hospital Essen, Essen, Germany

4. IRCCS AOU di Bologna, Bologna, Italy

5. Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), Vienna, Austria.

Abstract

Abstract Studies with [68Ga]Ga-labeled or [18F]F-labeled fibroblast activation protein inhibitor compounds have demonstrated favorable characteristics for PET/CT imaging, making them especially interesting for digestive tumors. In this review, the recent evidence in this field and its potential clinical applications are discussed.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference17 articles.

1. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0;Eur J Nucl Med Mol Imaging,2015

2. EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA);Eur J Nucl Med Mol Imaging,2021

3. Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0 [published correction appears in Eur J Nucl Med Mol Imaging 2022;49:3300–3301];Eur J Nucl Med Mol Imaging,2022

4. European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): lung cancer;Lung Cancer,2020

5. Agreement between 18F-FDG PET/CT and whole-body magnetic resonance compared with skeletal survey for initial staging and response at end-of-treatment evaluation of patients with multiple myeloma;Clin Nucl Med,2021

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fibroblast Activation Protein Inhibitor (FAPI) PET Imaging in Sarcomas: A New Frontier in Nuclear Medicine;Seminars in Nuclear Medicine;2024-05

2. How to Perform FAPI PET? An Expedited Systematic Review Providing a Recommendation for FAPI PET Imaging With Different FAPI Tracers;Seminars in Nuclear Medicine;2023-12

3. Discordant Uptake of Leg Thrombi Versus Pulmonary Emboli on 68Ga-FAPI-46 PET/CT;Clinical Nuclear Medicine;2023-10-05

4. FAP expression in alpha cells of Langherhans insulae—implications for FAPI radiopharmaceuticals’ use;European Journal of Nuclear Medicine and Molecular Imaging;2023-05-04

5. Multitracer PET/CT with [18F]Fluorodeoxiglucose and [18F]Fluorocholine in the Initial Staging of Multiple Myeloma Patients Applying the IMPeTus Criteria: A Pilot Study;Diagnostics;2023-04-27